title: Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer.
abstract: OBJECTIVE
  Second-line chemotherapy in patients with metastatic gastric cancer (MGC) pre-treated with cisplatin is not a standard option. We studied a combination of irinotecan, fluorouracil and folates.
  
  
  METHODS
  Patients progressive to cisplatin-based chemotherapy were enrolled. Irinotecan 180 mg/m(2), folinic acid 200 mg/m(2), and fluorouracil 400 mg/m(2) were given on day 1, immediately followed by fluorouracil 2,400 mg/m(2) 46 h continuous infusion (simplified FOLFIRI), every 2 weeks.
  
  
  RESULTS
  Between June 2002 and May 2003, 28 patients were treated. Median age was 57 years (range 38-68). Most patients had a distal primary (90%), and metastatic disease (71%). Partial response was obtained in six patients (21%, 95% CI 8-41) and stable disease in eight (21%, 95% CI 13-41). Among the six responsive patients three were refractory to docetaxel. At a median follow-up of 2.9 years median time to progression was 4 months (95% CI: 2-5), and median overall survival was 5 months (95% CI 4-9). Toxicity was mild, without treatment-related deaths or life-treating adverse events.
  
  
  CONCLUSIONS
  Simplified FOLFIRI was moderately active and well tolerated in unselected patients with MGC pre-treated with cisplatin-based chemotherapy. Its role in patients refractory to taxanes is promising and warrants further investigation.
authors.affiliation: Department of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. katia.lorizzo@ieo.it
authors.forename: Katia
authors.initials: K
authors.lastname: Lorizzo
authors.forename: Nicola
authors.initials: N
authors.lastname: Fazio
authors.forename: Davide
authors.initials: D
authors.lastname: Radice
authors.forename: Sabrina
authors.initials: S
authors.lastname: Boselli
authors.forename: Leonardo
authors.initials: L
authors.lastname: Ariu
authors.forename: Maria Giulia
authors.initials: MG
authors.lastname: Zampino
authors.forename: Franco
authors.initials: F
authors.lastname: Nolè
authors.forename: Elena
authors.initials: E
authors.lastname: Magni
authors.forename: Raffaele
authors.initials: R
authors.lastname: Ardito
authors.forename: Ida
authors.initials: I
authors.lastname: Minchella
authors.forename: Andrea
authors.initials: A
authors.lastname: Rocca
authors.forename: Giovanni
authors.initials: G
authors.lastname: Di Meglio
authors.forename: Michela
authors.initials: M
authors.lastname: Squadroni
authors.forename: Filippo
authors.initials: F
authors.lastname: de Braud
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D011788:Quality of Life; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin